Kalos Therapeutics

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Kalos Therapeutics

Kalos Therapeutics is a biomedical company with the exclusive patent to develop the ANP (atrial natriuretic peptide) family of peptides as a new mechanism for the treatment of cancer.[1]

Kalos has been covered by ABC News [2] on Good Morning America, and profiled in Business Week[3] and Time Magazine.[4] The company aggressively targets diseases caused by an abnormally high growth rate of cells (hyper proliferation),[5] and is pioneering an approach to cancer treatment by developing peptides made primarily in the heart, as a cytostatic therapeutic for treating aggressive cancers by engaging known pathway receptors more efficiently without the side effects associated with chemotherapeutic or small molecule compounds.[6]

KT-220, the current lead drug candidate, demonstrates remarkably broad anti-cancer activity. KT-220 has inhibited the growth of pancreatic, lung, prostate, breast, ovarian, colon, and melanoma cells in culture and of pancreatic, breast, and lung cancer tumors in models of human cancer.[7]

Board Members[edit]

George Colberg - Chairman & CEO

James Merritt, M.D. - President and Chief Medical Officer

Gregory F. Witchel, MBA - Executive Vice President

Daniel Von Hoff, MD, FACP - Chairman, Scientific Advisory Board

David L. Vesely, MD, PhD - Scientific Advisory Board

Marc B. Garnick, MD - Scientific Advisory Board

Patrice P Rioux, MD, PhD - Scientific Advisory Board

Derek E Vest - Secretary

Affiliated Organizations[edit]

Covidien, Translational Genomics Research Institute, Gentech Pharmaceutical, Arizona College of Ophthalmology, MonoSol RX, Q Chip


External Links